Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06821659
What this trial is testing

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

Who this might be right for
Systemic Lupus ErthematosusSystemic Sclerosis (SSc)Inflammatory Myopathies+2 more
Peking University Third Hospital 9
Early research (Phase 1)WithdrawnNCT04556266
What this trial is testing

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Who this might be right for
LeukemiaLymphomaLymphoma, B-Cell
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)UnknownNCT06212154
What this trial is testing

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Who this might be right for
Autoimmune Hemolytic AnemiaCD19 CAR-T Cell Infusion
Institute of Hematology & Blood Diseases Hospital, China 13
Early research (Phase 1)UnknownNCT03767725
What this trial is testing

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Shenzhen Second People's Hospital 10
Early research (Phase 1)WithdrawnNCT07093086
What this trial is testing

Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
B-cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Early research (Phase 1)Study completedNCT02529813
What this trial is testing

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Who this might be right for
Acute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaBlasts 5 Percent or More of Bone Marrow Nucleated Cells+6 more
M.D. Anderson Cancer Center 26
Early research (Phase 1)Looking for participantsNCT06285279
What this trial is testing

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Who this might be right for
Lupus NephritisANCA-associated VasculitisMembranous Nephropathy - PLA2R Induced+1 more
Nanjing University School of Medicine 24
Early research (Phase 1)UnknownNCT02546739
What this trial is testing

Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Who this might be right for
LeukemiaLymphoma
Beijing Doing Biomedical Co., Ltd. 100
Very early researchLooking for participantsNCT04512716
What this trial is testing

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Who this might be right for
B-ALLDLBCLB ALL+8 more
Memorial Sloan Kettering Cancer Center 12
Very early researchUnknownNCT05747157
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Anhui Provincial Hospital 18
Not applicableUnknownNCT06373081
What this trial is testing

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Who this might be right for
Systemic Lupus Erythematosus (SLE)Sjogren's SyndromeSystemic Sclerosis+3 more
Shanghai Changzheng Hospital 6
Very early researchTemporarily pausedNCT07604792
What this trial is testing

FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.

Who this might be right for
Autoimmune Diseases
Beijing Boren Hospital 9
Very early researchLooking for participantsNCT07586267
What this trial is testing

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

Who this might be right for
Autoimmune DiseasesSystemic Lupus Erthematosus (SLE)Multi-Drug Resistant Nephrotic Syndrome+3 more
The Children's Hospital of Zhejiang University School of Medicine 15
Testing effectiveness (Phase 2)Looking for participantsNCT05667506
What this trial is testing

CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd. 47
Early research (Phase 1)Looking for participantsNCT05010564
What this trial is testing

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Who this might be right for
Leukemia, B-Cell
Baylor College of Medicine 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT02028455
What this trial is testing

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

Who this might be right for
CD19+ Acute Leukemia
Seattle Children's Hospital 167
Early research (Phase 1)Looking for participantsNCT06649227
What this trial is testing

Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19

Who this might be right for
Relapsed Adult AML
University Hospital, Lille 5
Testing effectiveness (Phase 2)Looking for participantsNCT07081646
What this trial is testing

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Who this might be right for
Relapsed AL AmyloidosisRefractory AL AmyloidosisLight Chain Amyloidosis+1 more
Alexion Pharmaceuticals, Inc. 91
Not applicableNot Yet RecruitingNCT06993766
What this trial is testing

The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

Who this might be right for
Relapsed B-ALLCAR T-cellsCD19-directed CAR T-cell Therapy
King Faisal Specialist Hospital & Research Center 100
Next Page